PAD and Dyslipidemia – Deciphering the Intricacies of Therapeutic Options

What’s new in lipid management for people with polyvascular disease and symptomatic peripheral arterial disease (PAD)?

Our host, Dr. George Thanassoulis, takes a deeper look into this topic with Dr. Priya Manjoo, an Endocrinologist and Certified Specialist in both Hypertension and Obesity Medicine at the Victoria Cardiometabolic Collaborative Clinic, and a Clinical Assistant Professor in the Division of Endocrinology at the University of British Columbia’s Faculty of Medicine.

This episode discusses how the recently updated Canadian Cardiovascular Society Guidelines have changed the clinical practice of lipid management in patients wtih polyvascular disease and symptomatic PAD. Our experts expand on why this patient subgroup is at significantly higher risk for future cardiovascular events, highlighting the importance of timely diagnosis and identification of these patients. They also discuss how initiation of more intensive treatments that aim to further lower LDL cholesterol, such as PCSK9 inhibitors, can reduce the cardiovascular risk in these patients.

Don’t miss the conversation!

The views and opinions expressed in this episode are those of the speakers and do not necessarily reflect the views or positions of any entities they represent.

Declaration of conflict of interest:

Dr.  Thanassoulis:

• Direct financial relationship including receipt of honoraria: Sanofi. Membership on advisory boards or speaker’s bureau: Sanofi, Amgen, Novartis, Silence.

Dr. Manjoo:

• Direct financial relationship including receipt of honoraria: Amgen, Novo Nordisk, Bosch health, HLS therapeutics. Membership on advisory boards or speaker’s bureau: Novo Nordisk, Bosch health. Lilly, Amgen bone health.